Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28560564 | 0.91 | MEN1 (0.60) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL25407355 | 0.91 | MEN1 (0.60) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL12901343 | 0.91 | MEN1 (0.60) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL4755749 | 0.91 | MEN1 (0.60) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL16798226 | 0.88 | MEN1 (0.57) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL13109074 | 0.88 | MEN1 (0.57) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL16798225 | 0.88 | MEN1 (0.57) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL6242898 | 0.88 | KMT2A (0.57) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL13109049 | 0.88 | MEN1 (0.61) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL13109033 | 0.88 | MEN1 (0.61) | MEN1GAAKMT2ATDP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12478696-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250114485-A1 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-04-10 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20230113481-A1 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11491245-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-11-08 | — | — | US | disclosed |
| EP-3611169-B1 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-107667096-B | Novel gadolinium chelate compounds for magnetic resonance imaging | 拜耳医药股份公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2006053782-A1 | AMIDE AND PEPTIDE DERIVATIVES OF DIALKYLENETRIAMINES AND THEIR USE AS TRANSFECTION AGENTS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6991775-B2 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
| CN-1599577-A | Peptide-based multimeric targeted contrast media | EPIX MEDICAL INC (US) | 2005-03-23 | — | — | CN | disclosed |
| EP-1420681-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | Epix Medical, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | Factor 1A, LLC | 2003-11-20 | — | — | US | disclosed |
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003011115-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX MEDICAL, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478696-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | GLRA1, GLRA3, GLRB | MEN1 2981/4885GAA 3363/4885KMT2A 3852/4885 |
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-11491245-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | GLRA1, GLRA3, GLRB | MEN1 2879/4885GAA 3767/4885KMT2A 3983/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | MEN1 871/4885GAA 3639/4885KMT2A 2617/4885 |
| US-20230113481-A1 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | GLRA1, GLRA3, GLRB | MEN1 3236/4885GAA 3681/4885KMT2A 3832/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | MEN1 1151/4885GAA 2669/4885KMT2A 229/4885 |
| US-20250114485-A1 | GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | GLRA1, GLRA3, GLRB | MEN1 2981/4885GAA 3363/4885KMT2A 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.